- Home
- CLBT vs BLCO Comparison
CLBT vs BLCO Comparison
Compare CLBT & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLBT
- BLCO
- Stock Information
- Founded
- CLBT 1999
- BLCO 1853
- Country
- CLBT Israel
- BLCO Canada
- Employees
- CLBT N/A
- BLCO N/A
- Industry
- CLBT Computer Software: Prepackaged Software
- BLCO Ophthalmic Goods
- Sector
- CLBT Technology
- BLCO Health Care
- Exchange
- CLBT Nasdaq
- BLCO Nasdaq
- Market Cap
- CLBT 4.1B
- BLCO 4.4B
- IPO Year
- CLBT N/A
- BLCO 2022
- Fundamental
- Price
- CLBT $15.47
- BLCO $11.70
- Analyst Decision
- CLBT Strong Buy
- BLCO Hold
- Analyst Count
- CLBT 7
- BLCO 13
- Target Price
- CLBT $22.43
- BLCO $15.63
- AVG Volume (30 Days)
- CLBT 1.5M
- BLCO 598.0K
- Earning Date
- CLBT 08-14-2025
- BLCO 07-30-2025
- Dividend Yield
- CLBT N/A
- BLCO N/A
- EPS Growth
- CLBT N/A
- BLCO N/A
- EPS
- CLBT N/A
- BLCO N/A
- Revenue
- CLBT $419,170,000.00
- BLCO $4,829,000,000.00
- Revenue This Year
- CLBT $20.75
- BLCO $6.97
- Revenue Next Year
- CLBT $17.32
- BLCO $5.48
- P/E Ratio
- CLBT N/A
- BLCO N/A
- Revenue Growth
- CLBT 22.04
- BLCO 11.94
- 52 Week Low
- CLBT $11.47
- BLCO $10.45
- 52 Week High
- CLBT $26.30
- BLCO $21.69
- Technical
- Relative Strength Index (RSI)
- CLBT 29.64
- BLCO 45.65
- Support Level
- CLBT $15.69
- BLCO $11.44
- Resistance Level
- CLBT $16.30
- BLCO $12.70
- Average True Range (ATR)
- CLBT 0.51
- BLCO 0.36
- MACD
- CLBT -0.02
- BLCO 0.01
- Stochastic Oscillator
- CLBT 4.23
- BLCO 30.07
About CLBT Cellebrite DI Ltd.
Cellebrite DI Ltd is an Israeli digital intelligence company that provides tools for federal, state, and local law enforcement as well as enterprise companies and service providers to collect, review, analyze, and manage digital data. Some of its products include Cellebrite UFED, Cellebrite Physical Analyzer, Cellebrite UFED Cloud, Cellebrite Frontliner, Cellebrite Responder, Cellebrite Premium, and Cellebrite Seeker.
About BLCO Bausch + Lomb Corporation
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.